Seer, Inc.
SEERHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeSeer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan,. At a $115.5M market cap, Seer, Inc. ranks as a micro-cap company within healthcare. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Market Cap
$115.5M
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
-2.14
EPS (TTM)
$-1.28
EPS (Fwd)
$-0.98
ROE
-25.5%
ROA
-15.0%
Cash
$166.7M
Total Debt
$23.0M
Free CF
-$31.7M
52W Change
-2.3%
Annual Financials
Cash vs Debt
Where SEER stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, SEER finished 17.39% above its 150-day moving average ($1.84) and 12.50% above its 200-day moving average ($1.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SEER overbought or oversold?
At the July 15, 2026 close, SEER's RSI(14) was 74.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $166.7M in cash comfortably exceeding the $23.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$31.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -25.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $14.7M (2022) to $16.1M (2025).
With a beta above 1.5, SEER tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Seer, Inc. and its sector.